SCHEMBL2270787

SCHEMBL2270787

Cc1ccccc1-c1ccc(C(=O)O)c(NC(=O)c2ccccc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
PKM P14618 2/20 0.57
MAPT P10636 2/20 0.57
GRIK1 P39086 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
NR1H4 Q96RI1 1/20 0.56
MCL1 Q07820 1/20 0.56
ACLY P53396 1/20 0.55
POLB P06746 1/20 0.55
HPGD P15428 1/20 0.55
DHODH Q02127 1/20 0.54
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
SERPINE1 P05121 1/20 0.50
FTO Q9C0B1 1/20 0.50
FFAR1 O14842 1/20 0.49
HDAC2 Q92769 3/20 0.49
HDAC1 Q13547 2/20 0.49
CYP1A2 P05177 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2270209 0.91 NPC1 (0.54) MEN1KMT2APKMMAPTGRIK1
SCHEMBL2273941 0.86 ACLY (0.59) MEN1KMT2APKMMAPTGRIK1
SCHEMBL2270215 0.86 MEN1 (0.51) MEN1KMT2APKMMAPTGRIK1
SCHEMBL2272986 0.86 SERPINE1 (0.60) MEN1KMT2APKMMAPTGRIK1
SCHEMBL2273647 0.85 ACLY (0.60) MEN1KMT2APKMMAPTGRIK1
SCHEMBL2276609 0.85 PKM (0.59) MEN1KMT2APKMMAPTGRIK1
SCHEMBL12118092 0.85 ACLY (0.52) NR1H4MCL1ACLYDHODHNPC1
SCHEMBL2269324 0.84 POLB (0.47) MEN1KMT2APKMMAPTGRIK1
SCHEMBL1317201 0.84 ACLY (0.51) NR1H4MCL1ACLYDHODHNPC1
SCHEMBL2270359 0.84 MEN1 (0.57) MEN1KMT2APKMMAPTGRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 MEN1 3105/4885KMT2A 1669/4885PKM 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.